Recce Pharmaceuticals Ltd Cash Flow Conversion Efficiency

Latest as of June 2026: -0.020x

Recce Pharmaceuticals Ltd cash flow conversion efficiency. Based on the latest financial reports, Recce Pharmaceuticals Ltd (RCE) has a cash flow conversion efficiency ratio of -0.020x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$341.10K ≈ $241.35K USD) by net assets (AU$-16.72 Million ≈ $-11.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Recce Pharmaceuticals Ltd (2014–2026)

Cash flow conversion efficiency of Recce Pharmaceuticals Ltd from 2014 to 2026. This chart illustrates how Recce Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RCE live share price for real-time trading data and today's change.

Recce Pharmaceuticals Ltd Cash Flow Conversion Ratio Explained

Recce Pharmaceuticals Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Recce Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Recce Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. Also see Recce Pharmaceuticals Ltd stock valuation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Ahn-Gook Pharmaceutical Co. Ltd KQ:001540	0.086x
NWF GROUP PLC LS-25 F:NYY	N/A
AFC Gamma Inc NASDAQ:AFCG	0.003x
Soosan Heavy I KO:017550	-0.003x
IBU tec advanced materials AG XETRA:IBU	0.255x
Real Estate & E-Commerce Split Corp TO:RS	-0.015x
Kukdong Oil & KO:014530	0.071x
Tasco Bhd KLSE:5140	0.022x

Annual Cash Flow Conversion Efficiency for Recce Pharmaceuticals Ltd (2014–2026)

The table below shows the annual cash flow conversion efficiency of Recce Pharmaceuticals Ltd from 2014 to 2026. Review Recce Pharmaceuticals Ltd (RCE) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2026-06-30	AU$-16.72 Million ≈ $-11.83 Million	AU$-9.89 Million ≈ $-7.00 Million	0.592x	-91.17%
2025-06-30	AU$-3.05 Million ≈ $-2.16 Million	AU$-20.44 Million ≈ $-14.46 Million	6.698x	+390.36%
2024-06-30	AU$-9.52 Million ≈ $-6.74 Million	AU$-13.01 Million ≈ $-9.20 Million	1.366x	-72.13%
2023-06-30	AU$-2.59 Million ≈ $-1.83 Million	AU$-12.69 Million ≈ $-8.98 Million	4.901x	+647.26%
2022-06-30	AU$10.06 Million ≈ $7.12 Million	AU$-9.01 Million ≈ $-6.38 Million	-0.896x	-133.73%
2021-06-30	AU$20.50 Million ≈ $14.51 Million	AU$-7.86 Million ≈ $-5.56 Million	-0.383x	+76.73%
2020-06-30	AU$2.31 Million ≈ $1.64 Million	AU$-3.81 Million ≈ $-2.69 Million	-1.646x	-125.56%
2019-06-30	AU$-405.60K ≈ $-286.99K	AU$-2.61 Million ≈ $-1.85 Million	6.440x	+358.34%
2018-06-30	AU$694.91K ≈ $491.70K	AU$-1.73 Million ≈ $-1.23 Million	-2.493x	+41.10%
2017-06-30	AU$590.14K ≈ $417.56K	AU$-2.50 Million ≈ $-1.77 Million	-4.233x	-825.16%
2016-06-30	AU$3.51 Million ≈ $2.49 Million	AU$-1.61 Million ≈ $-1.14 Million	-0.458x	-628.29%
2015-06-30	AU$4.71 Million ≈ $3.34 Million	AU$-296.14K ≈ $-209.54K	-0.063x	+69.36%
2014-06-30	AU$-55.74K ≈ $-39.44K	AU$11.43K ≈ $8.09K	-0.205x	--

About Recce Pharmaceuticals Ltd

AU:RCE Australia Biotechnology

Market Cap

$71.40 Million

AU$100.90 Million AUD

Market Cap Rank

#20281 Global

#679 in Australia

Share Price

AU$0.33

Change (1 day)

+0.00%

52-Week Range

AU$0.27 - AU$0.71

All Time High

AU$1.68